Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
Related Questions
Would you favor culprit-only PCI, complete revascularization via percutaneous approach, or urgent CABG evaluation for a young diabetic patient with newly reduced LVEF < 35% presenting with an anterior STEMI and multivessel disease?
In light of recent trials evaluating NPO before cath (CHOW NOW, SCOFF, etc.) are centers still restricting oral intake pre-procedure?
What are your preferred guide catheters to use for engaging coronaries in patients with mechanical or bioprosthetic aortic valves?
When is a reasonable amount of time for patients to be on 90mg BID of ticagrelor before transitioning to 60mg BID following PCI?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
Do you prefer the routine use of bivalirudin over UFH during PCI cases in patients presenting with ACS?
How do you manage anticoagulation/antiplatelet therapies with strong indications for uninterrupted therapy in setting of urgent procedures?
For patients presenting with suspected type 1 NSTEMI and atrial fibrillation on anticoagulation, do you favor triple therapy or SAPT with systemic anticoagulation instead while awaiting LHC?
How do you approach the decision of when to perform left heart catheterization in a patient with an NSTEMI who recently had an acute ischemic stroke?
In patients with post-MI LV thrombus which resolves after 3-6 months of anticoagulation, would you consider surveillance imaging for thrombus recurrence if there is persistent apical akinesis?
